CNSP
NASDAQ · Pharmaceuticals
Cns Pharmaceuticals Inc
$7.29
+0.19 (+2.68%)
Financial Highlights (FY 2025)
Revenue
401.0K
Net Income
137.9K
Gross Margin
52.4%
Profit Margin
34.4%
Rev Growth
+21.3%
D/E Ratio
0.24
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 52.4% | 52.4% | 52.4% |
| Operating Margin | 35.7% | 31.9% | 32.9% |
| Profit Margin | 34.4% | 34.2% | 33.1% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 401.0K | 379.4K | 323.5K |
| Gross Profit | 209.9K | 198.6K | 169.4K |
| Operating Income | 143.2K | 121.0K | 106.4K |
| Net Income | 137.9K | 129.6K | 106.9K |
| Gross Margin | 52.4% | 52.4% | 52.4% |
| Operating Margin | 35.7% | 31.9% | 32.9% |
| Profit Margin | 34.4% | 34.2% | 33.1% |
| Rev Growth | +21.3% | -7.8% | +5.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 306.2K | 352.4K | 387.0K |
| Total Equity | 1.29M | 1.09M | 1.24M |
| D/E Ratio | 0.24 | 0.32 | 0.31 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 186.8K | 161.4K | 136.4K |
| Free Cash Flow | 134.0K | 130.1K | 98.1K |